Imfinzi for Non Small Cell Lung Cancer User Reviews
Imfinzi has an average rating of 8.7 out of 10 from a total of 3 reviews for the treatment of Non Small Cell Lung Cancer. 100% of reviewers reported a positive experience, while 0% reported a negative experience.
- jkp...
- Taken for 6 months to 1 year
- August 15, 2024
"Cancer in remission just before 10th treatment. Many skin problems. Dry, cracking skin on sides and bottom of feet. Dry skin on arms and legs. Occasional mild headaches, terrible problems sleeping at night. All problems on mild side."
- Anonymous
- Taken for 6 months to 1 year
- April 1, 2024
"Had 12 treatments after completion of chemoradiation. Medication was well tolerated with minimal side effects."
Frequently asked questions
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about Imfinzi (durvalumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
"Also using to treat myeloma. Started taking late 2016. Seems to keep both cancers at bay. I have had some very strange lung infections. Not sure if related to treatment. My hair is very dry, thin, limp. Dry skin. Frequent urination. Fatigue. Restless nights. Depression. Body aches. I’m a 60-year-old male."